openPR Logo
Press release

Migraine Drugs Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030

08-12-2023 07:38 AM CET | Health & Medicine

Press release from: Orion Market Research

Migraine Drugs Market Share, Trends, Future Outlook, Analysis

The global migraine drugs market is projected to grow at a CAGR of over 9% during the forecast period. The global migraine drugs industry has several players operating in the market and providing products for the treatment of migraine globally. Some of the prominent players operating in the global migraine drugs market are Allergan Plc, Amgen Inc., Novartis International AG, Eli Lilly & Co., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc. Pfizer Inc., and Teva Pharmaceuticals Inc. among others. These players are significantly contributing to the global migraine drugs market and have a major share during the forecast period.

A full report of Global Migraine Drugs Market is available at: https://www.omrglobal.com/industry-reports/migraine-drugs-market

Some of the strategies that are majorly being adopted by these players include new products offering, expansion, partnership & collaboration, and mergers & acquisitions among others. For instance, Allergan's Ubrogepant and Eli Lilly's Lasmiditan are the migraine drugs based on the advanced mechanism of action.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/migraine-drugs-market

In February 2020, Biohaven Pharmaceutical Holding Co. Ltd.'s oral pill known as Nurtec ODT, chemically known as rimegepant was approved by the US FDA. This drug is consumed for dismissing the pain after the onset of migraine headaches. The dug falls under CGRP and directly competes with the first approved Allergan Plc's Ubrelvy.

In December 2019, the migraine drug Ubrogepant (Ubrelvy) manufactured by Allergen Plc has been approved by the US FDA. Ubrogepant is the CGRP drug in tablet form which is meant to be taken immediately after the onset of migraines by adults.

In September 2018, Ajovy, a migraine drug manufactured by Teva Pharmaceutical Industries Ltd. received US regulatory approval. Ajovy is an injectable drug that is to be taken in a few months for relieving migraines in adults.

In May 2018, Aimovig, the drug manufactured by Amgen Inc. received the US FDA approval. The drug is given monthly by self-injection and charges up to $575 monthly in the US. The company manufactured Aimovig in partnership with Novartis International AG, a Swiss multinational pharmaceutical company.

Current Market Trends Covered in the Global Migraine Drug Market Report:

Increased healthcare spending and improving healthcare infrastructure is influencing the global migraine drugs industry growth during the forecast period.

Shifting consumer preferences towards the use of injections for a quicker relief is expected to provide ample growth opportunities for market growth.
The injection segment will account for significant growth in the market.

The novel drug innovations, various regulatory approvals, and geographical expansions will be the key strategy of the players.

North America region is expected to hold a prominent share in the migraine drugs market.

Global Migraine Drugs Market - Segmentation

By Type

Acute Migraine Treatment
Preventive Migraine Treatment

By Route of Administration

Oral
Injectable
Others (Spray)

Global Migraine Drugs Market - Segmentation by Region

North America

United States
Canada

Europe

Germany
United Kingdom
France
Spain
Italy
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of Asia-Pacific

Rest of the World

Middle East & Africa
Latin America

Company Profiles

Allergan Plc
Amgen Inc.
Astrazeneca PLC
Bausch Health Companies Inc.
Biohaven Pharmaceutical Holding Co. Ltd.
Reddy's Laboratories Ltd.
Eli Lilly & Co.
GlaxoSmithKline Plc
Lundbeck A/S
Johnson & Johnson Services Inc.
Merck & Co. Inc.
Mylan N.V.
Novartis International AG
Neurelis, Inc.
Pfizer Inc.
Sanofi SA

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Migraine Drugs Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030 here

News-ID: 3163460 • Views:

More Releases from Orion Market Research

EConsent in Healthcare Market Set to Witness Significant Growth by 2033 | Veeva Systems, eConsent Solutions, Phlexglobal, Mytrus
EConsent in Healthcare Market Set to Witness Significant Growth by 2033 | Veeva …
The EConsent in Healthcare Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 3.8 billion by 2033, growing at a CAGR of 12.5% from 2025 to 2033. EConsent in Healthcare Market Overview The EConsent in Healthcare Market is witnessing strong growth as healthcare providers increasingly adopt digital consent solutions to streamline patient onboarding, clinical trials, and data-sharing processes. The shift toward electronic health records (EHRs),
Property Management Software (PMS) Market Set to Witness Significant Growth by 2033 | AppFolio, Inc., MSI Solutions, Guestline, Maestro PMS
Property Management Software (PMS) Market Set to Witness Significant Growth by 2 …
The Property Management Software (PMS) Market was valued at USD 4.2 billion in 2024 and is projected to reach USD 10.1 billion by 2033, growing at a CAGR of 10.1% from 2025 to 2033. Property Management Software (PMS) Market Overview The Property Management Software Market is experiencing significant growth as real estate, hospitality, and facility management sectors increasingly adopt digital solutions to streamline operations. PMS enables efficient management of property listings,
Mobile Battery Market Set to Witness Significant Growth by 2033 | Sony Corporation, Toshiba Corporation, ATL (Amp Technology Limited)
Mobile Battery Market Set to Witness Significant Growth by 2033 | Sony Corporati …
The Mobile Battery Market was valued at USD 21.4 billion in 2024 and is projected to reach USD 39.8 billion by 2033, growing at a CAGR of 7.0% from 2025 to 2033. Mobile Battery Market Overview The Mobile Battery Market is witnessing strong growth, driven by the increasing adoption of smartphones, tablets, wearable devices, and other portable electronics. Rising consumer demand for longer battery life, fast charging, and enhanced energy density
DevSecOps Market Set to Witness Significant Growth by 2033 | Checkmarx Ltd., Snyk Ltd., Fortinet Inc., Micro Focus International plc
DevSecOps Market Set to Witness Significant Growth by 2033 | Checkmarx Ltd., Sny …
The DevSecOps Market was valued at USD 5.6 billion in 2024 and is projected to reach USD 17.4 billion by 2033, growing at a CAGR of 12.3% from 2025 to 2033. DevSecOps Market Overview The DevSecOps Market is witnessing significant growth as organizations increasingly integrate security practices into DevOps processes to ensure secure software development. The rising frequency of cyberattacks, stringent regulatory requirements, and growing adoption of cloud-native applications are driving

All 5 Releases


More Releases for Migraine

Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share? The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size? The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market? The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes. Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market. The objectives outlined in the report are multifaceted and aimed at offering a comprehensive
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases. The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs. Get Access to TOC /